Titan Pharmaceuticals Company Profile (OTCMKTS:TTNP)

About Titan Pharmaceuticals (OTCMKTS:TTNP)

Titan Pharmaceuticals logoTitan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:TTNP
  • CUSIP: N/A
  • Web: www.titanpharm.com/
Capitalization:
  • Market Cap: $41.35 million
  • Outstanding Shares: 21,203,000
Average Prices:
  • 50 Day Moving Avg: $2.11
  • 200 Day Moving Avg: $3.06
  • 52 Week Range: $1.75 - $6.40
P/E:
  • Trailing P/E Ratio: 15.48
  • Foreward P/E Ratio: -4.88
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $15.1 million
  • Price / Sales: 2.74
  • Book Value: $0.50 per share
  • Price / Book: 3.90
Profitability:
  • EBIDTA: $3.12 million
  • Net Margins: -7,512.50%
  • Return on Equity: -101.29%
  • Return on Assets: -75.95%
Misc:
  • Average Volume: 153,913 shs.
  • Short Ratio: 4.94
 
Frequently Asked Questions for Titan Pharmaceuticals (OTCMKTS:TTNP)

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TTNP."

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) released its earnings results on Wednesday, May, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. Titan Pharmaceuticals had a negative net margin of 7,512.50% and a negative return on equity of 101.29%. View Titan Pharmaceuticals' Earnings History.

Where is Titan Pharmaceuticals' stock going? Where will Titan Pharmaceuticals' stock price be in 2017?

1 analysts have issued 1-year price targets for Titan Pharmaceuticals' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Titan Pharmaceuticals' stock price to reach $10.00 in the next year. View Analyst Ratings for Titan Pharmaceuticals.

Who are some of Titan Pharmaceuticals' key competitors?

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the folowing people:

  • Marc Rubin M.D., Executive Chairman of the Board
  • Sunil Ramraje Bhonsle, President, Director
  • Rajinder Kumar, Director
  • Scott A. Smith, Director
  • Joseph A. Akers, Independent Director
  • Eurelio M. Cavalier, Independent Director
  • M. David David MacFarlane Ph.D., Independent Director

Who owns Titan Pharmaceuticals stock?

Titan Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Municipal Employees Retirement System of Michigan (1.43%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Joseph A Akers, Marc Rubin and Sunil Bhonsle. View Institutional Ownership Trends for Titan Pharmaceuticals.

Who bought Titan Pharmaceuticals stock? Who is buying Titan Pharmaceuticals stock?

Titan Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Joseph A Akers, Marc Rubin and Sunil Bhonsle. View Insider Buying and Selling for Titan Pharmaceuticals.

How do I buy Titan Pharmaceuticals stock?

Shares of Titan Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of Titan Pharmaceuticals stock can currently be purchased for approximately $1.95.


MarketBeat Community Rating for Titan Pharmaceuticals (OTCMKTS TTNP)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  51
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Titan Pharmaceuticals (OTCMKTS:TTNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00

Analysts' Ratings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Show:
DateFirmActionRatingPrice TargetDetails
3/20/2017Roth CapitalSet Price TargetBuy$10.00View Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Earnings by Quarter for Titan Pharmaceuticals (OTCMKTS:TTNP)
Earnings History by Quarter for Titan Pharmaceuticals (OTCMKTS TTNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.15)($0.16)$0.09 million$0.04 millionViewN/AView Earnings Details
11/9/2016Q316($0.11)($0.12)$0.25 million$0.03 millionViewListenView Earnings Details
5/10/2016Q116($0.12)($0.09)ViewListenView Earnings Details
3/15/2016Q415($0.10)($0.11)ViewListenView Earnings Details
8/13/2015($0.02)($0.02)$0.86 million$0.76 millionViewN/AView Earnings Details
5/13/2015($0.03)($0.04)$0.66 million$0.91 millionViewN/AView Earnings Details
3/31/2015($0.01)($0.01)$0.91 million$0.91 millionViewN/AView Earnings Details
11/13/2014($0.02)($0.01)$0.90 million$0.91 millionViewN/AView Earnings Details
8/13/2014($0.02)($0.01)$0.90 million$0.91 millionViewN/AView Earnings Details
11/15/2013Q3 13($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Titan Pharmaceuticals (OTCMKTS:TTNP)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.40 EPS

Dividends

Dividend History for Titan Pharmaceuticals (OTCMKTS:TTNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Insider Trades by Quarter for Titan Pharmaceuticals (OTCMKTS:TTNP)
Insider Trades by Quarter for Titan Pharmaceuticals (OTCMKTS:TTNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/19/2016Joseph A AkersDirectorBuy13,000$4.85$63,050.00View SEC Filing  
7/18/2016Sunil BhonsleCEOBuy10,000$4.96$49,600.00View SEC Filing  
5/31/2016James R McnabDirectorBuy20,000$7.03$140,600.00View SEC Filing  
2/22/2016Sunil BhonsleCEOBuy11,763$3.56$41,876.28View SEC Filing  
1/15/2016Sunil BhonsleCEOBuy5,841$2.72$15,887.52View SEC Filing  
1/13/2016James R McnabDirectorBuy16,363$3.16$51,707.08View SEC Filing  
1/11/2016Marc RubinChairmanBuy5,000$3.25$16,250.00View SEC Filing  
1/11/2016Sunil BhonsleCEOBuy17,000$3.18$54,060.00View SEC Filing  
9/16/2015Sunil BhonslePresidentBuy10,000$0.70$7,000.00View SEC Filing  
8/28/2015Marc RubinChairmanBuy50,000$0.72$36,000.00View SEC Filing  
8/25/2015Sunil BhonslePresidentBuy50,000$0.70$35,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Titan Pharmaceuticals (OTCMKTS:TTNP)
Latest Headlines for Titan Pharmaceuticals (OTCMKTS:TTNP)
Source:
DateHeadline
finance.yahoo.com logoTitan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate to Evaluate ProNeura Antimalarial Implants
finance.yahoo.com - July 6 at 2:43 PM
finance.yahoo.com logoFortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology
finance.yahoo.com - June 29 at 7:36 AM
finance.yahoo.com logoTTNP: First Quarter Results; Development Programs on Track.
finance.yahoo.com - May 16 at 8:34 PM
americanbankingnews.com logoTitan Pharmaceuticals, Inc. (TTNP) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 11 at 2:46 PM
finance.yahoo.com logoEdited Transcript of TTNP earnings conference call or presentation 10-May-17 8:15pm GMT
finance.yahoo.com - May 11 at 9:23 AM
finance.yahoo.com logoTitan Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 10:11 AM
finance.yahoo.com logoETFs with exposure to Titan Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 11:42 PM
finance.yahoo.com logoTitan Pharmaceuticals Schedules Conference Call To Review First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 10:07 AM
americanbankingnews.com logoTitan Pharmaceuticals (TTNP) Earns Daily News Impact Rating of 0.23
www.americanbankingnews.com - April 24 at 6:51 PM
americanbankingnews.com logoTitan Pharmaceuticals (TTNP) Receives Media Sentiment Score of 0.16
www.americanbankingnews.com - April 21 at 9:40 PM
finance.yahoo.com logoETFs with exposure to Titan Pharmaceuticals, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 11:06 PM
finance.yahoo.com logoTTNP: 2016 Results; Deep Dive on Development Programs
finance.yahoo.com - March 27 at 7:34 PM
americanbankingnews.com logoTitan Pharmaceuticals, Inc. (TTNP) PT Set at $10.00 by Roth Capital
www.americanbankingnews.com - March 24 at 7:32 AM
us.rd.yahoo.com logoTitan Pharmaceuticals Reports Full Year And Fourth Quarter 2016 Financial Results
us.rd.yahoo.com - March 17 at 3:42 AM
biz.yahoo.com logoQ4 2016 Titan Pharmaceuticals Inc Earnings Release - Time Not Supplied
us.rd.yahoo.com - March 17 at 3:42 AM
biz.yahoo.com logoTITAN PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 3:42 AM
us.rd.yahoo.com logoTitan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results
us.rd.yahoo.com - March 11 at 9:42 PM
finance.yahoo.com logoTitan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results - Yahoo Finance
finance.yahoo.com - March 11 at 8:28 AM
finance.yahoo.com logoTitan Pharmaceuticals To Present At 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 8:35 AM
us.rd.yahoo.com logoTitan Pharmaceuticals Receives FDA Communication On Ropinirole Implant Investigational New Drug Application
us.rd.yahoo.com - February 28 at 11:22 AM
biz.yahoo.com logoTITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events
biz.yahoo.com - February 27 at 8:45 AM
finance.yahoo.com logoFast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
finance.yahoo.com - February 14 at 6:41 AM
seekingalpha.com logoMarket Analysis: Titan's Probuphine Faces Challenges Ahead - Seeking Alpha
seekingalpha.com - February 8 at 8:07 AM
us.rd.yahoo.com logoBraeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services
us.rd.yahoo.com - January 14 at 6:41 AM
us.rd.yahoo.com logo8:09 am Titan Pharma announces that the Centers for Medicare & Medicaid Services has granted a permanent J-code for Probuphine for the maintenance treatment of opioid addiction; the new J-code became effective January 1, 2017
us.rd.yahoo.com - January 14 at 6:41 AM
biz.yahoo.com logoTITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 10 at 2:56 AM
biz.yahoo.com logoTITAN PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
biz.yahoo.com - January 5 at 7:17 AM
finance.yahoo.com logoTitan Pharmaceuticals Appoints Two New Board Members
finance.yahoo.com - January 4 at 7:16 AM
investorplace.com logo10 Pharmaceuticals Stocks to Sell Now - Investorplace.com
investorplace.com - December 24 at 3:11 AM
finance.yahoo.com logoTTNP: Training Providers and Securing Payors; 3Q:16 Results
finance.yahoo.com - November 21 at 8:34 PM
finance.yahoo.com logoBraeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year
finance.yahoo.com - November 21 at 8:34 PM

Social

Chart

Titan Pharmaceuticals (TTNP) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff